ClinicalTrials.gg
RecruitingNCT07629960Updated Sep 21, 2026

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

A Phase 1/2 interventional study of BLU-924 in Advanced Solid Tumor, Non-Small Cell Lung Cancer and Colorectal Neoplasms, sponsored by Blueprint Medicines Corporation. Recruiting at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
265
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Carcinoma, Non-Small-Cell Lung by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Sanofi.

Planned enrollment
7th of 42
265 · median 69
Started
2026
the only one that year
Phase 1/2
3 of 47
1 open now
Registered
47th of 47
by date

Among the 47 studies in Carcinoma, Non-Small-Cell Lung by Sanofi, this one is the 7th largest by planned enrollment of the 42 interventional ones that give a count, is the only one that started in 2026, is one of 3 in phase 1/2, and was the 47th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 47 studies in Carcinoma, Non-Small-Cell Lung by Sanofi is open now, in 2 countries.

By country, each count listing its studies:

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Carcinoma, Non-Small-Cell Lung by Sanofi, or all of them as a file.
02

Study summary

A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

Read the detailed description

This is an open-label, multi-center, Phase 1/2 study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of BLU-924, a pan-KRAS inhibitor, in participants with metastatic KRAS mutant pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), or colorectal cancer (CRC). The monotherapy part of the study includes Dose Escalation, Dose Enrichment, and Dose Expansion. Participants enrolled during Dose Escalation and Dose Enrichment will be evaluated for dose limiting toxicities (DLTs) to determine the MTD. Participants enrolled into disease-specific Enrichment cohorts will enable a more robust characterization of safety, PK, pharmacodynamics, and preliminary clinical activity. Enrolment into Dose Expansion will follow the identification of at least 1 recommended dose for expansion (RDFE) based on data from the Dose Escalation and Dose Enrichment. No combination arm is active at this time.

03

Conditions studied

  • Advanced Solid Tumor
  • Non-Small Cell Lung Cancer
  • Colorectal Neoplasms
  • Pancreatic Ductal Adenocarcinoma

Keywords

  • Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
  • Metastatic Non-Small Lung Cell Cancer
  • Metastatic Colorectal Cancer (CRC)
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • KRAS G12A
  • KRAS G12C
  • KRAS G12D
  • KRAS G12S
  • KRAS G12V
  • Solid Tumor, Adult
  • KRAS-mutant
  • KRAS-positive
  • KRAS G13D
  • Pan-KRAS inhibitor
  • KRAS inhibitor
  • First-in-human
  • Solid tumor
  • Advanced cancer
  • Adult solid tumor
  • Metastatic solid tumor
  • Colorectal cancer
  • Colon cancer
  • Rectal cancer
  • Metastatic colorectal cancer
  • Pancreatic cancer
  • Pancreatic ductal adenocarcinoma
  • PDAC
  • Metastatic pancreatic cancer
  • Lung cancer
  • NSCLC
  • Precision oncology
  • Targeted therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed diagnosis of Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), or colorectal cancer (CRC) with evidence of a single KRAS G12C, G12D, G12V, G12A, G12S, or G13D mutation in tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA).
  2. by (RECIST) v1.1.
  3. (ECOG) performance status (PS) 0-1.
  4. Patients must have received all standard therapies for their cancer type in the metastatic setting, unless they are unable to receive such therapies due to clinical characteristics, comorbidities, or other medically justified reasons.

Exclusion criteria

Exclusion Criteria:

  1. History of additional within the last 2 years, with some exceptions as specified in the protocol.
  2. Active (participants with asymptomatic brain metastases may be eligible).
  3. Have received prior targeted treatment(s) against KRAS, including pan-KRAS inhibitors, multi-RAS inhibitors, mutant-selective KRAS inhibitors, and RAS or KRAS degraders.
  4. Active or uncontrolled systemic infection, such as tuberculosis, virus (HBV), virus (HCV), or (HIV).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
265 participants (estimated)

Study arms

  • Experimental
    Monotherapy Part: BLU-924 Dose Escalation, Dose Enrichment, and Dose Expansion

    Participants will receive BLU-924 oral tablet, once daily as monotherapy during Dose Escalation followed by Dose Enrichment. During Dose Enrichment, participants with PDAC, NSCLC or CRC will receive BLU-924 at selected dose levels below the current escalation dose or, if Dose Escalation is complete, below the MTD. During Dose Expansion, participants will receive RDFE of BLU-924 oral tablet, once daily as monotherapy determined during escalation monotherapy part. Dose Expansion may be initiated to further assess the safety, antitumor activity, PK, and pharmacodynamics of BLU-924 at RDFE in indication-specific cohorts (PDAC, NSCLC, or CRC) harboring a KRAS mutation.

    Drug: BLU-924

Interventions

  • DrugBLU-924

    Tablet

    Also known as: SAR449336

06

What researchers measure

Primary outcomes

  1. Dose Escalation and Enrichment: Percentage of Participants with Dose-limiting Toxicity (DLTs)

    Any of the prespecified AEs that are attributable to the study treatment, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes.

    Time frame: Up to 5 years

  2. Dose Escalation, Enrichment and Expansion: Incidence and Severity of Treatment-emergent Adverse Events (TEAEs) and Serious AEs

    An adverse event (AE) is any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it.

    Time frame: Up to 5 years

  3. Dose Escalation and Enrichment: Maximum Tolerated Dose (MTD) of BLU-924

    Time frame: Up to 5 years

  4. Dose Escalation and Enrichment: Recommended Dose for Expansion (RDFE) of BLU-924

    Time frame: Up to 5 years

  5. Dose Expansion: Overall Response Rate (ORR)

    Time frame: Up to 5 years

Secondary outcomes

  1. Dose Escalation and Enrichment: Overall Response Rate (ORR)

    Time frame: Up to 5 years

  2. Dose Escalation, Enrichment, and Expansion: Duration of Response (DOR)

    Time frame: Up to 5 years

  3. Dose Escalation, Enrichment, and Expansion: Disease Control Rate (DCR)

    Time frame: Up to 5 years

  4. Dose Escalation, Enrichment and Expansion: Progression-free Survival (PFS)

    Time frame: Up to 5 years

  5. Dose Expansion: Overall Survival (OS)

    Time frame: Up to 5 years

  6. Dose Escalation, Enrichment and Expansion: AUC - Area Under the Plasma Concentration Time Curve for BLU-924

    Time frame: Up to 2 years

  7. Dose Escalation, Enrichment and Expansion: Cmax - Maximum Plasma Concentration for BLU-924

    Time frame: Up to 2 years

  8. Dose Escalation, Enrichment and Expansion: Cmin - Minimum Plasma Concentration of BLU-924

    Time frame: Up to 2 years

  9. Dose Escalation, Enrichment and Expansion: Tmax - Time to Maximum Plasma Drug Concentration for BLU-924

    Time frame: Up to 2 years

  10. Dose Escalation, Enrichment and Expansion: t1/2 - Terminal Half-life of BLU-924

    Time frame: Up to 2 years

  11. Dose Escalation, Enrichment and Expansion: CL/F - Apparent Oral Clearance of BLU-924

    Time frame: Up to 2 years

  12. Dose Escalation, Enrichment and Expansion: Vc/F- Apparent Volume of Central Compartment of BLU-924

    Time frame: Up to 2 years

  13. Dose Escalation, Enrichment and Expansion: Vd- Volume of Distribution of BLU-924

    Time frame: Up to 2 years

07

Study locations

3 of 16 sites recruiting
  • Florida Cancer Specialists & Research Institute - Sarasota
    Sarasota, Florida 34242, United States
    Recruiting
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
  • Mary Bird Perkins Cancer Center
    Baton Rouge, Louisiana 70809, United States
    Not yet recruiting
  • Massachusetts General Hospital - Main Campus
    Boston, Massachusetts 02114, United States
    Not yet recruiting
  • University of Michigan Medical School Rogel Cancer Center
    Ann Arbor, Michigan 48109-5843, United States
    Not yet recruiting
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601-2191, United States
    Not yet recruiting
  • NYU Langone Health Perlmutter Cancer Center
    New York, New York 10016, United States
    Not yet recruiting
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
    Not yet recruiting
  • The University of Texas MD Anderson Cancer Center - Texas Medical Center
    Houston, Texas 77030, United States
    Not yet recruiting
  • Next Oncology Virginia Cancer Specialist
    Fairfax, Virginia 22031, United States
    Recruiting
  • Mi Cancer Center Barcelona (Pratia Sirius Barcelona)
    Barcelona, Catalonia 08017, Spain
    Not yet recruiting
  • Hospital Universitario Vall d'Hebron
    Barcelona, Catalonia 08035, Spain
    Not yet recruiting
  • Hospital General Universitrio Gregorio Maranon
    Madrid, Madrid 28007, Spain
    Not yet recruiting
  • Hospital Universitario 12 de Octubre
    Madrid, Madrid 28009, Spain
    Not yet recruiting
  • NEXT Oncology - Madrid
    Pozuelo de Alarcón, Madrid 28223, Spain
    Not yet recruiting
  • Clinica Universidad de Navarra (CUN)
    Pamplona, Navarre 31008, Spain
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2029, 39 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 39 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 5, 2026
StartActual
Jun 4, 2026
Primary completionEst.
Sep 2029
CompletionEst.
Jul 2031
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07629960
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Jun 4, 2026
Primary completion
Sep 2029 (estimated)
Completion
Jul 2031 (estimated)
Last update
Sep 21, 2026

Study contacts

Blueprint Medicines
Contact
medinfo@blueprintmedicines.com
1-888-258-7768

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion